Four chemically similar alkaloids, anabasine, anabaseine, epibatidine and dimethylphenylpiperazinium (DMPP), are potent nicotinic acetylcholine receptor agonists of fetal muscle nicotinic acetylcholine receptors in human TE-671 cells. Based on results with these cells, we hypothesized that the alkaloids would completely inhibit ultrasound-monitored fetal movement in a goat model. Different, single doses of anabasine, anabaseine, epibatidine, DMPP, or saline control were administered I.V. to pregnant goats on day 40 of gestation and the number of fetal movements per 5 min sample was measured by ultrasound at times 0, 0.5, 1, 2, 4 and 8 h. The differences among does in fetal movements were more consistent at dosing and following recovery for doses of anabasine above 0.125 mg/kg compared to the other compounds and dosages. Anabasine actions were dose-dependent with an IC 50 value of~0.1 mg/kg, and, at a dose of 0.8 mg/kg, completely inhibited fetal movement for 1.5 h after dosing. Anabaseine, epibatidine, and DMPP failed to completely inhibit fetal movement in day 40 pregnant goats at doses predicted to be effective. These results suggest that while experiments with TE-671 cells provide valuable information and predictions of the actions of plant alkaloids on fetal movement, in vivo experiments are still required in order to determine the ability of an alkaloid to inhibit fetal movement in livestock species. Moreover, other pharmacological properties such as receptor differences between mammalian species and differences in the pharmacokinetic properties of the alkaloids also are likely to weaken teratologic predictions based solely on the in vitro data.
Introduction
Anabasine and anabaseine are related piperidine alkaloids (Fig. 1 ). Anabasine contains a saturated piperidine ring while anabaseine possesses a double bond alpha to the nitrogen in its piperidine ring which is conjugated with double bond electrons in its pyridyl ring. Both compounds are potent, efficacious agonists and receptor desensitizers at fetal human muscle-type nicotinic acetylcholine receptors (nAChR) expressed by TE-671 cells (Table 1) . The presence of an imine double bond in the piperidine ring, like in anabaseine, has been postulated to increase teratogenicity (Panter et al., 1994) . Anabasine, although somewhat less potent in TE-671 cells than anabaseine, is a demonstrated teratogen and a minor alkaloid in common tobacco (Nicotiana tabacum) and a highly prevalent alkaloid in tree tobacco (Nicotiana glauca) (Saitoh et al., 1985) . Dried ground tree tobacco produces fetal defects in the offspring of cattle, goat, pigs and sheep (Panter et al., 1990; Panter and Keeler, 1992; Keeler et al., 1981a,b; Crowe, 1983, 1984) . These defects include arthrogryposis, kyphosis, lordosis, scoliosis, and torticollis, and are termed multiple congenital contracture-type (MCC-type) deformities. Based upon results from the tree tobacco dosing experiments, researchers at this laboratory have hypothesized that these fetal defects are due to the complete and sustained inhibition of fetal movement (Bunch et al., 1992; Weinzweig et al., 2008; Welch et al., 2015) . For example, when pregnant goats were orally dosed with 200 g of dried ground N. glauca on day 45 of pregnancy, fetal movement was inhibited for 5 h and after repeated dosing for 30 days MCC-type deformities were documented in 11 of 11 kids (Panter et al., 1990) . We have also reported that a dose of 0.8 mg/kg anabasine Abbreviations: DMPP, dimethylphenylpiperazinium; nAChR, nicotinic acetylcholine receptor.administered IV to pregnant goats on the 40 th day of gestation completely inhibits fetal movement up to 60 min after dosing (Green et al., 2013b) . Note that nicotine, which is also a pyridinering containing alkaloid, does not completely inhibit fetal movement and thus is not thought to cause MCC-type deformities in livestock (For review see Green et al., 2013c,d) .
In contrast to anabasine, the inhibitory actions of anabaseine on fetal movement are unknown, and other than rodent studies, relatively little is known about the in vivo effects of anabaseine (Kem et al., 1997 . Anabaseine was initially isolated from a marine nemertine worm (Kem et al., 1971) . Dwoskin et al. (1995) has classified anabaseine as a minor tobacco alkaloid; although it has been identified in tobacco (Duffield et al., 1965) , it is thought to be a degradation product of anabasine in the plant (Kisaki and Tamaki, 1966) . We have postulated, based on its agonist potency and efficacy at fetal muscle-type nAChRs expressed by TE-671 cells, that anabaseine would be a more effective livestock teratogen than anabasine (Green et al., 2010) . We also predicted based on results from cell culture experiments that anabaseine would inhibit fetal movement at lower concentrations than anabasine due to the double bond in its piperidine ring which increases its potency and efficacy at nAChR (Panter et al., 1999; Green et al., 2010) . However, this hypothesis is based upon structure-activity relationships and on fetal human nAChR cell culture data. If results from cell-based experiments are to be used to predict compound teratogenesis in livestock, the actions of compounds like anabaseine must be verified in vivo in order to test the validity of the cell-based model. Moreover, until this report, anabaseine has not been evaluated in a pregnant goat model to determine if it inhibits fetal movement which is the putative mechanism behind the formation of the MCCtype defects associated with teratogenic piperidine alkaloids like anabasine and coniine (Table 1) . Both anabasine and coniine have been confirmed to completely inhibit fetal movement when dosed I.V. as pure compounds and are known teratogens in livestock (Green et al., 2013a,b) . Panter et al. (1999) has also suggested that in order to be teratogenic in livestock, an alkaloid must induce a complete, succinylcholine-like neuromuscular block of fetal movement. This hypothesis suggests that an alkaloid must completely inhibit fetal movement using the day-40 pregnant goat model for the alkaloid to be considered teratogenic.
In addition to anabasine and anabaseine, we also examined the effects of the potent cholinergic agonist epibatidine (first identified in the poison frog Epipedobates tricolor by Spande et al. (1992) ), dimethylphenylpiperazinium (DMPP) a nAChR agonist selective for ganglionic (a3b4) nAChR (Chen et al., 1951) and a saline control. The purpose of this research was to determine if in vitro data for four potent nAChR agonists obtained with TE-671 cells (Table 1) could predict whether inhibition of fetal movement occurs in an in vivo goat model.
Materials and methods

Drugs
Saline was obtained from MWI Animal Health (Boise, Idaho). (±)-Epibatidine dihydrochloride hydrate and 1,1-Dimethyl-4-phenylpiperazinium iodide (DMPP, MW 318) were obtained from Millipore Sigma Chemical Company (Burlington, Massachusetts; United States of America). Anabasine free base (MW 162) was purified as from N. glauca as previously described (Lee et al., 2006) . Anabaseine dihydrochloride monohydrate (MW 251) was synthesized as previously described (Zoltewicz et al., 1989; Bloom, 1990) . The alkaloids were freshly prepared on the day of each goat experiment by dissolving them in physiological saline and then sterile filtered through a 0.22 mm syringe filter (EMD Millipore, Billerica, MA, U.S.A.).
Animal care and use
All work with goats was done under veterinary supervision and approval of the Utah State University Institutional Animal Care and Use Committee. The experiments were conducted over the course of the 2015e2016 (NovembereFebruary) breeding season and the 2016e2017 (NovembereFebruary) breeding season.
Dose determination
In order to determine the doses of anabaseine, epibatidine and DMPP, yearling wether goats were dosed I.V. on a mg/kg body weight basis to identify the dose of alkaloid needed to produce similar clinical signs of intoxication as 0.8 mg/kg anabasine including salivation, urination, defecation and muscle fasciculations while resting on their sternum. We have previously shown that a 0.8 mg/kg dose of anabasine inhibits fetal movement at 30 min and 1 h after i. v. dosing (Green et al., 2013b) . The doses of alkaloids used in this study were chosen in an effort to decrease the risk of MCC-type defects (a goal of <3 h inhibition of ultrasoundmonitored fetal movement). Past research from this laboratory has shown that prolonged inhibition of fetal movement (>5 h) is required to produce MCC-type defects (see Panter et al., 1990 ).
Alkaloid administration
The estrous cycles of 34 Spanish-type female goats weighing 36.6 ± 1.4 kg were synchronized using Chrono-gest vaginal sponges containing 40 mg Flugestone acetate (also known as a controlled internal drug release dispenser (CIDR)) (Intervet International B.V. Boxmeer, Holland). Approximately 24e48 h after sponge removal, the does were bred by Spanish-type bucks. The last day the doe accepted the buck was considered day zero of gestation. The does were maintained ad libitum on water, trace-mineralized salt blocks (iOFIXT T-M, Morton Salt Corporation, Chicago, IL), and alfalfa hay for 40 days from when they were last bred by the buck. At approximately gestation day 36, the pregnancy status of the does was verified by ultrasound. At day 40 of gestation, the compounds were administered to the does I.V. on a mg/kg body weight basis starting at approximately 7 am. The number of fetal movements for a single fetus per goat per 5 min sampling period were measured by ultrasound at 0, 0.5, 1, 2, 4 and 8 h after dosing using an Aloka UST model 990-5 probe (Model SSD-3500, Aloka Corporation, Wallingford, CT) and Medline ultrasound gel (Medline Industries, Northfield, IL) as previously described (Green et al., 2013b) .
Data analysis
Nonlinear regression (log (inhibitor) verses response normalized to the number of movements at time zero) was performed with Prism version 5.04 (GraphPad Software, San Diego, CA). We chose to model the dose-response curve with the number of fetal movements at the 1 h time-point for anabasine. For movement to be considered completely inhibited, the mean number of movements at a time-point was required to be zero.
Results
This experiment was designed to completely inhibit fetal movement for <3 h and as a result, no MCC-type defects were observed in any of the kids from the pregnant does dosed with any of the compounds in this study. Anabasine (Fig. 2, Supplemental  Fig.1 ) affected ultrasound-monitored fetal movements in a dose and time dependent manner that was also dependent on the goat, with goats that had more movement at time 0 recovering sooner and with more movements upon recovery. At the smallest dose administered, 0.002 mg/kg anabasine (n ¼ 5 does), anabasine produced no apparent clinical signs (salivation, urination, defecation and muscle fasciculations) in the pregnant does. The smallest alkaloid dose also had no effect on fetal movements and the variation in goat clinical response was inconsistent and varied across time (for example, goat G144). At a dose of 0.08 mg/kg (n ¼ 4 does), anabasine did not completely inhibit fetal movement and did not affect the does. At a dose of 0.125 mg/kg of anabasine (n ¼ 5 does) there were minor clinical signs (urination and defecation) immediately after dosing, and fetal movements dropped to near zero at 0.5 h after dosing, but then rapidly recovered. When the 0.44 mg/kg anabasine (n ¼ 5 does) dose was administered, clinical signs (salivation, urination, defecation and muscle fasciculations) were more apparent in the does. Fetal movements were an average of zero at 0.5 h, and then increased to 0.5 ± 0.5% of the baseline normalized movements at 1 h. At 0.44 mg/kg anabasine there were more extreme individual goat differences of fetal movements with observable fetal movements in one doe at 1 h after dosing (G131), while another doe (G146) remained at zero fetal movements until 2 h post-dosing and subsequently recovered slowly thereafter and the remaining does were in between these responses. Anabasine dosed at 0.8 mg/kg produced the most significant clinical signs of intoxication in the pregnant does which included; salivation, urination, defecation and muscle fasciculations. The 0.8 mg/kg dose (n ¼ 4 does) completely inhibited movement at 0.5 and 1 h, but at 2 h after dosing there was an average 0.9 ± 0.5% of the baseline movements. The IC 50 value obtained from responses to the five anabasine doses at 1 h after IV administration was 0.1 mg/kg (95% confidence intervals, 0.05e0.3 mg/kg).
Anabaseine was dosed at 0.002 mg/kg (n ¼ 4 does) and 0.125 mg/kg (n ¼ 8 does). The 0.002 mg/kg dose did not produce any noticeable signs in the pregnant does and the 0.125 mg/kg dose of anabasine produced clinical signs of intoxication similar to 0.8 mg/kg anabasine. The mean actions of anabaseine on fetal movement are displayed in Fig. 3 and the individual goat responses are displayed in Supplemental Fig. 2 . The 0.002 mg/kg dose of anabaseine had no consistent effects on fetal movement and the 0.125 mg/kg anabaseine dose was less consistent across individual does than the same dose of anabasine at inhibiting fetal movement. There was considerable animal to animal variation in fetal movements across does for the initial critical time period from 30 min to 2 h with only 1 doe having near 0 movements for the entire 1.5 h period. On the other hand, all 4 does dosed with 0.125 mg/kg anabasine (Supplemental Fig. 1 ) displayed similar decreases in fetal movements from 30 min to 2 h. Because anabaseine did not completely inhibit fetal movement, it did not meet the criteria to be classified as a possible teratogen using this model.
We also dosed 0.002 mg/kg epibatidine (n ¼ 5 does), 0.8 mg/kg DMPP (n ¼ 5 does), and 3 ml of saline (n ¼ 7 does) (Fig. 4,  Supplemental Fig. 3 ). Epibatidine at 0.002 mg/kg and DMPP at 0.8 mg/kg produced clinical signs of intoxication similar to a 0.8 mg/kg dose of anabasine, while saline was without effect on the pregnant doe and its fetuses. Both DMPP and epibatidine failed to completely inhibit fetal movement at any time during the course of the 8 h ultrasound monitoring period. Because epibatidine and DMPP did not completely inhibit fetal movement they did not meet the criteria to be classified as potential teratogens using this model. Individually, epibatidine dosed at 0.002 mg/kg reduced fetal movements to near zero from 30 min to 2 h for only one of the 5 does tested and doe differences were not consistent over time following dosing. Similarly, DMPP dosed at 0.8 mg/kg resulted in fetal movements dropping to near zero for only 1 of 5 does and this drop was delayed by 30 min compared to responses to anabasine. Doe differences were inconsistent across time following dosing for DMPP and epibatidine. Differences among does given saline were inconsistent over time showing similar variability to the low dosages of anabasine and anabaseine.
Discussion
Results from experiments with anabasine suggest that its effects on fetal movement are dose-dependent with an IC 50 value of 0.1 mg/kg (Fig. 2a) . The larger doses of anabasine completely inhibited fetal movement, suggesting it is a teratogen in this model, i.e., capable of inhibiting fetal movement in goats. MCC-type defects were not observed in the offspring of the does dosed with anabasine due to the limited time-span of complete inhibition of fetal movement from a single I.V. dose of anabasine. Recent research at this laboratory has shown that sustained, complete inhibition of fetal movement is required to cause MCC-type defects with anabasine. For example, Welch et al. (2015) used an oral dose of 5.5 mg/kg anabasine in the form of dried ground tree tobacco administered twice daily for an extended period of time to produce MCC-type defects in goats. In this study, we administered only a single dose of anabasine intravenously to the pregnant goats and the inhibition of fetal movement was not sustained long enough to cause terata. Although there were no MCC-type defects in the offspring of does dosed with anabasine, it meets our definition of a teratogen because it caused complete inhibition of ultrasoundmonitored fetal movement. Anabasine has been shown in numerous studies to induce MCC-type deformities (Panter et al., 1990; Panter and Keeler, 1992; Keeler et al., 1981a,b; Crowe, 1983, 1984) . Interestingly, when the individual goat responses to anabasine are examined (Supplemental Fig. 1) , the goat differences in response to anabasine were more apparent during recovery from higher doses (0.125, 0.44 and 0.8 mg/kg) suggesting that the number of movements reflect variation in responses of goats to the alkaloid. It is tempting to speculate that animals with increased fetal movement at 4e8 h after I.V., dosing may be more resistant to the effects of poisonous plants with these alkaloids and have a desirable phenotype that could be selected for.
At this laboratory, we have previously shown that piperidine alkaloids must provide a sustained and complete inhibition of fetal movement to cause terata in livestock and Panter et al. (1994) has hypothesized that the presence of an imine double bond in the piperidine ring, like in anabaseine, increases teratogenicity. As our research interests in teratogenic alkaloids has expanded, we turned to cell-based experiments to measure the potency and efficacy of these nAChR agonists, and made predictions of teratogenicity based on these in vitro characteristics of a MCCtype teratogen (Green et al., 2010 (Green et al., , 2016 (Green et al., , 2017 . We hypothesized that the more potent an agonist is at fetal muscle-type nAChR expressed by TE-671 cells, the more effective it will be at desensitizing nAChR and at inhibiting fetal movement in a goat model. However, this hypothesis is based entirely upon cell culture experiments (Table 1) , not on the putative mechanism of MCC-type defect formation, the inhibition of fetal movement. For that reason, we decided to test three potent cholinergic agonists; anabaseine, epibatidine, and DMPP in a goat model. While the larger 0.125 mg/kg dose of anabaseine did cause clinical signs of intoxication equal to 0.8 mg/kg anabasine in the pregnant does, it did not completely abolish fetal movement. This fetal movement result was unexpected because cell culture studies have shown that anabaseine is a very potent nAChR agonist and desensitizer with a DC 50 value of 0.6 mM relative to an anabasine DC 50 value of 2.3 mM (Table 1) , about a 4-fold difference. Interestingly, in the pregnant goats, the 0.125 mg/kg anabaseine dose produced clinical signs equivalent to the 0.8 mg/kg anabasine dose about a 6-fold difference in potency for that response. Results from this work suggest that clinical signs of intoxication in pregnant does is not a substitute for direct ultrasound observation of fetal movement. When the 0.125 mg/kg dose of anabaseine (Fig. 3b, Supplemental Fig. 1 ) is compared to the 0.125 mg/kg dose of anabasine (Fig. 2d,  Supplemental Fig. 2) , anabasine was more effective at reducing fetal movement even though it is a much less potent cholinergic agonist in TE-671 cells and the anabasine clinical signs were much less at that dose (urination and defecation). Another unexpected result from this work was that epibatidine did not completely inhibit fetal movement (Fig., Supplemental Fig. 3 ), even though it is an extremely potent nicotinic agonist (Badio and Daly, 1994) and results from our TE-671 cell culture experiments suggested it would inhibit ultrasound-monitored fetal movement (DC 50 ¼ 0.3 mM). Moreover, epibatidine was dosed to pregnant does at 400-fold lesser dose than the largest dose of anabasine but with equivalent clinical signs. Finally, we tested DMPP to determine the role of ganglionic nAChR in the inhibition of fetal movement and it moderately decreased movement in goats which suggests that ganglionic (a3b4) nAChR are not involved in the complete inhibition of fetal movement. The lack of inhibition of fetal movement by anabaseine, epibatidine, and DMPP was unexpected because in TE-671 cells, the EC 50 and DC 50 values of the three alkaloids were less than 1 mM (Table 1) . We expected fetal movements to be completely inhibited for up to 2 h as we observed for anabasine (Fig. 2) which suggests that although cell-based models are useful for measuring relative potencies and efficacies of agonist activation and desensitization at nAChRs, they may not be the best model for predicting the ability of an alkaloid to inhibit fetal movement in livestock. In particular, cellbased models do not take into account the fetal compartment, and differences in the pharmacokinetic properties of the alkaloids, the role of the placenta in toxin action, the developmental stage of the fetus, or the genotype and phenotype of the fetus in response to xenobiotic exposure. Cell-based models may also not be that useful for alkaloids which are very weak agonists like the quinolizidine alkaloid, anagyrine (EC 50 ¼ 231 mM DC 50 ¼ 139 mM, in TE-671 cells, Green et al., 2017) which is an effective inhibitor of fetal movement and known teratogen in cattle (Green et al., 2015) .
In conclusion, we hypothesized that anabasine, anabaseine, epibatidine, and DMPP which are potent and effective agonists at fetal muscle-type nAChR expressed by TE-671 cells, would be effective at completely inhibiting fetal movement in a goat model. Results from experiments with day 40 pregnant goats support the hypothesis for anabasine and suggest that the null hypothesis is true for anabaseine, epibatidine, and DMPP because they did not completely inhibit fetal movement. Results from this work also suggest that clinical signs of intoxication in pregnant animals cannot be substituted for direct ultrasound observation of fetal movement. Finally, TE-671 cell-based predictions of the actions of plant alkaloids on fetal movement are not as reliable as actual in vivo experiments in order to determine the potential of an alkaloid to cause developmental defects in livestock species.
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